Antiretroviral Drug Interactions [1 Mainpro credit:193017-001]

Webinar Main Objectives:

  1. Identify common drug interactions between antiretrovirals and other medications
  2. Identify and access antiretroviral drug interaction resources
  3. Be aware of scenarios where drug interactions might be missed

The webinar will be presented by:

Kathy Lepik
Research Coordinator, Pharmacovigilance Initiative
BC Centre for Excellence in HIV/AIDS

Facilitator: Junine Toy, Senior Manager for the Drug Treatment Program, BC-CfE

The presentation will be followed by a question and answer period where participants will have the opportunity to ask questions and receive real time responses from the presenter.


Cost: Free registration.

Please register for the webinar by

clicking here.

This event is accredited by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1 Mainpro+ credits.

If you are unable to attend the live webinar it will be recorded and available for viewing on BC-CfE’s Education and Training website at: education.cfenet.ubc.ca/webinars.

For questions related to this event please contact: education@cfenet.ubc.ca


Event Details

Days
Hours
Minutes
Seconds
Start Date
End Date
Event Category
Attendees of the BC-CfE Learning Series will be able to:
  • Summarize and describe epidemiological, behavioural, virological, and other related research relevant to the management of people living with HIV and other syndemic conditions
  • Describe and demonstrate up-to-date information regarding the care of people living with HIV and syndemic conditions (including viral hepatitis and substance use) particularly in regards to primary care, antiretroviral therapy and other treatments, and comorbid conditions
  • Review new and emerging issues in the context of the management of people living with HIV and other syndemic conditions
  • Identify both clinical and community resources to support the care of people living with HIV and syndemic conditions.
Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below